Mind Medicine (MNMD) Quarterly EPS earnings growth

Mind Medicine - graphic logo of issuer MNMD

Mind Medicine is transforming psychiatry by developing innovative treatments for addiction and anxiety. A strong patent portfolio based on MDMA and LSD ensures long-term patient remission. Strict FDA and DEA oversight creates a high barrier to entry for competitors. The quarterly growth rate of net income per share demonstrates the fundamental resilience of the business, while the value of -184.90 shows the current magnitude of the metric.

MindMed (MNMD) - Year-over-year earnings per one share growth for the last 12 months from 07/04/2022 to 01/15/2026

Analytical breakdowns and data insights for company Mind Medicine (MNMD)

- share price and consensus valuation forecast:
Analysis of all company metrics:Mind Medicine
Manufactured product of Mind Medicine Corp

This indicator serves as a primary filter for the quantitative selection of promising assets. The metric captures the daily change in the growth rate of quarterly net earnings per share. By analyzing the EPS dynamics over a quarterly period, an investor can observe a smoothed profitability trajectory between reporting dates. For Mind Medicine (MNMD), this metric is secondary, as psychedelics are currently in the trial stage. The absence of commercialization renders current profit growth a purely technical factor.

Key competitors

ALKS (alkermes.com) - Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Avadel Pharma (AVDL)|ATAI (atai.life) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months GH Research PLC (GHRS)|Quarterly EPS earnings growth CMPS|LBRX (LB Pharmaceuticals, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months brightmindsbio.com DRUG|Vanda Pharmaceuticals (VNDA) - Earnings per share growth in annualized terms for the last twelve months|Cybin - Quarterly EPS earnings growth|ANRO - Quarterly EPS earnings growth|NRx Pharmaceuticals, Inc. (NRXP) - Year-over-year earnings per share growth for the last twelve months|CING - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Silo Pharma, Inc.|chinapharmaholdings.com (CPHI) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth CMND|Psyence Biomedical Ltd. - Year-over-year earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months SciSparc Ltd SPRC|Seelos Therapeutics Inc. (SEEL) - Earnings per share growth in annualized terms for the last twelve months|VRPX: Year-over-year net earnings per share growth for the last 12 months|KRTX - Quarterly EPS earnings growth